文献速递消化系统肿瘤

VIKTORY伞式试验:肿瘤基因组分析指导转移性胃癌靶向治疗

Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial.
PubMed 文献 · Cancer Discov · 2019-07-17

14.7%的患者接受了生物标志物指导的药物治疗,该队列对比常规二线化疗显示出鼓舞人心的缓解率和生存期。ctDNA分析显示高MET拷贝数与savolitinib疗效良好相关。

要点

  • 转移性胃癌患者临床测序可行,92.6%测序成功并可分入生物标志物组。
  • 仅14.7%患者接受生物标志物分配的药物治疗,但缓解率和生存期令人鼓舞。
  • ctDNA高MET拷贝数与savolitinib疗效良好相关。

核心结论

  • VIKTORY是胃癌首个且最大的平台研究,支持肿瘤分析可行且具有临床实用性。
  • 基线肿瘤样本异质性影响生物标志物选择治疗的应答。

研究设计与样本

  • VIKTORY伞式试验按临床测序将转移性胃癌分入8个生物标志物组并分配至10项二线治疗试验。

主要发现

  • 14.7%的患者接受了生物标志物分配的药物治疗。
  • 生物标志物分配治疗队列对比常规二线化疗显示出鼓舞人心的缓解率和生存期。
  • ctDNA高MET拷贝数与savolitinib应答良好相关。

临床怎么用

  • 对转移性胃癌患者可考虑临床测序以匹配靶向治疗试验。
  • ctDNA高MET拷贝数或可提示savolitinib治疗获益。

局限性

  • 基线肿瘤样本异质性影响生物标志物选择治疗的应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The VIKTORY (targeted agent eValuation In gastric cancer basket KORea) trial was designed to classify patients with metastatic gastric cancer based on clinical sequencing and focused on eight different biomarker groups (RAS aberration, TP53 mutation, PIK3CA mutation/amplification, MET amplification, MET overexpression, all negative, TSC2 deficient, or RICTOR amplification) to assign patients to one of the 10 associated clinical trials in second-line (2L) treatment. Capivasertib (AKT inhibitor), savolitinib (MET inhibitor), selumetinib (MEK inhibitor), adavosertib (WEE1 inhibitor), and vistusertib (TORC inhibitor) were tested with or without chemotherapy. Seven hundred seventy-two patients with gastric cancer were enrolled, and sequencing was successfully achieved in 715 patients (92.6%). When molecular screening was linked to seamless immediate access to parallel matched trials, 14.7% of patients received biomarker-assigned drug treatment. The biomarker-assigned treatment cohort had encouraging response rates and survival when compared with conventional 2L chemotherapy. Circulating tumor (ctDNA) analysis demonstrated good correlation between high MET copy number by ctDNA and response to savolitinib. SIGNIFICANCE: Prospective clinical sequencing revealed that baseline heterogeneity between tumor samples from different patients affected response to biomarker-selected therapies. VIKTORY is the first and largest platform study in gastric cancer and supports both the feasibility of tumor profiling and its clinical utility.This article is highlighted in the In This Issue feature, p. 1325.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Lee J, Kim ST, Kim K, et al. Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial. Cancer Discov. 2019. PMID: 31315834. doi:10.1158/2159-8290.CD-19-0442

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。